Form 8-K - Current report:
SEC Accession No. 0001493152-21-024665
Filing Date
2021-10-05
Accepted
2021-10-05 17:25:29
Documents
13
Period of Report
2021-10-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39230
  Complete submission text file 0001493152-21-024665.txt   265380

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ptix-20211001.xsd EX-101.SCH 3519
3 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ptix-20211001_def.xml EX-101.DEF 28203
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ptix-20211001_lab.xml EX-101.LAB 37634
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ptix-20211001_pre.xml EX-101.PRE 26409
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5868
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 211307838
SIC: 7389 Services-Business Services, NEC